The pharmaceutical industry has reached an inflection point. Traditional clinical trial data—once the gold standard—can no longer keep pace with the complexity of modern drug development, commercialization, and market access demands. Rising R&D costs (averaging $2.6 billion per approved drug), increasing regulatory scrutiny, and aggressive competition have forced pharma and medtech companies to fundamentally rethink how they generate evidence and make strategic decisions.
Enter real-world data (RWD), real-world evidence (RWE), and integrated healthcare datasets. These aren’t just buzzwords thrown around at industry conferences… they’re reshaping how commercial analytics teams forecast brand performance, how HEOR specialists demonstrate value to payers, and how regulatory affairs builds submission-grade evidence. The FDA’s 2023 guidance on RWE makes this explicit: real-world data can now support regulatory decision-making for both drugs and biologics when designed and analyzed appropriately.
But here’s what most pharma analytics teams are discovering the hard way: access to RWD isn’t enough. You need integrated, longitudinal datasets that link claims with EMR data, lab results, genomics, and patient-reported outcomes. You need advanced analytics capabilities—AI, machine learning, predictive modeling—to extract signal from noise. And you need all of this delivered in analysis-ready formats, not raw data dumps that require six months of data engineering before your first insight.
The Commercial Analytics Imperative: Why RWD Became Non-Negotiable
Commercial pharma teams are under enormous pressure. Launch excellence demands accurate market sizing and forecasting. Brand teams need competitive intelligence on prescribing patterns and patient journeys. Market access requires demonstrating real-world value to increasingly sophisticated payers. Portfolio planning depends on understanding disease burden and unmet needs across therapeutic areas.
Clinical trials alone can’t answer these questions. They’re too controlled, too narrow in patient selection, too short in duration. A Phase 3 oncology trial might enroll 500 carefully selected patients over 18 months. Real-world data from claims and EMRs can analyze treatment patterns across 50,000 patients over five years—including those with comorbidities, polypharmacy, and demographic diversity that trials explicitly exclude.
The FDA recognized this reality in their 2025 guidance on real-world evidence for medical devices and their 2024 draft guidance for drugs and biologics. Both documents acknowledge that RWD from sources like electronic health records, medical claims, product and disease registries, and patient-generated data can provide valid scientific evidence when appropriate methods are applied. This regulatory validation has accelerated pharma’s shift from “RWD as supplementary” to “RWD as foundational.”
Commercial analytics leaders I work with are leveraging RWD across the entire product lifecycle. During development, they’re sizing markets more accurately and identifying optimal patient populations. At launch, they’re tracking early adoption patterns and adjusting messaging in near-real-time. Post-launch, they’re demonstrating long-term safety and effectiveness to support label expansions and defend against payer restrictions. And throughout, they’re generating competitive intelligence that informs strategic positioning.
What Actually Constitutes Real-World Data—And Why Source Matters
Not all RWD is created equal. The term encompasses a remarkably diverse set of data sources, each with distinct strengths, limitations, and appropriate use cases.
Claims data from health insurance companies provides comprehensive information on diagnoses (coded in ICD-10), procedures, prescriptions (ATC codes, days supply), healthcare utilization, and costs. The major advantage? Near-universal coverage of insured populations with longitudinal tracking across providers. The limitation? Claims reflect billing documentation, not necessarily clinical detail—you know a patient filled a prescription, but not whether they actually took it or what their lab values were.
Electronic health records (EMRs/EHRs) offer richer clinical granularity: lab results, vital signs, clinical notes, imaging reports. But they’re fragmented across health systems and often contain unstructured data requiring natural language processing. Recent advances in EMR data aggregation—with specialized providers linking data from dozens of health systems—are making this source increasingly powerful for clinical research and outcomes analysis.
Registry data from disease-specific or procedure-specific registries provides highly curated clinical information with consistent definitions and data quality. Major European cardiovascular registries, for example, track detailed procedural and outcome data for cardiovascular interventions. The trade-off is limited scope—registries cover specific conditions or procedures, not broad population health.
Specialty pharmacy data has become increasingly valuable for high-cost biologics and rare disease treatments. These datasets often include more detailed patient support program information, adherence metrics, and outcomes tracking than standard pharmacy claims.
Social determinants of health (SDoH) data—regional-level information on income, education, housing, food security—is increasingly being linked to clinical data to understand health disparities and identify at-risk populations. This is particularly relevant for value-based care models and health equity initiatives.
According to a 2023 review in Pharmaceutical Medicine, the strategic value of RWD lies not just in individual sources but in their integration—creating comprehensive, longitudinal patient views that no single source provides. This is where integrated healthcare datasets become game-changing.
The Power of Integration: Linked Datasets and Longitudinal Patient Journeys
Here’s where pharma analytics gets genuinely transformative. When you link claims data with EMR data, genomic information, lab results, and patient-reported outcomes—all de-identified and tokenized for privacy—you create a 360-degree view of the patient journey that’s impossible from siloed sources.
Imagine tracking a newly diagnosed multiple myeloma patient from initial symptoms (EMR chief complaints and diagnostics) through diagnosis confirmation (lab values, imaging), treatment initiation (prescription claims), response monitoring (lab trends, hospitalizations), treatment switching (new prescription patterns), and long-term outcomes (survival, quality of life from patient surveys). This longitudinal perspective reveals treatment patterns, effectiveness, safety signals, and healthcare resource utilization in ways that fundamentally inform commercial strategy.
The technical challenge? Patient linkage across disparate systems while maintaining GDPR compliance. Modern approaches use tokenization—assigning unique identifiers that allow linking records without exposing personally identifiable information. Specialized data providers have invested heavily in linking methodologies that achieve 85-95% match rates while ensuring regulatory compliance.
The commercial applications are profound. Brand teams can analyze switching patterns when competitors launch—which patients switch, when, why (from claims patterns), and what predicts persistence. Market access teams can demonstrate real-world cost-effectiveness by linking treatment costs (claims) to outcomes (EMR lab values, hospitalizations). Portfolio planning can identify white spaces by analyzing treatment sequences and unmet needs across linked datasets showing both what patients receive and their clinical trajectories.
But—and this matters—integration quality varies dramatically. Some providers simply co-locate datasets without true patient-level linkage. Others use probabilistic matching that introduces significant error. The best integrated datasets use deterministic matching with validation against ground truth, achieving linkage rates above 90% with quality controls that ensure reliability for regulatory and HEOR applications.
Advanced Analytics: Turning Data Into Decisions
Raw data—even integrated data—doesn’t drive decisions. Advanced analytics transforms RWD into actionable insights. This is where AI, machine learning, and predictive modeling separate high-performing commercial organizations from those drowning in data.
A 2022 review in AAPS Journal examined machine learning applications across pharmaceutical research and development, highlighting how AI algorithms can identify prescribing patterns, predict patient outcomes, optimize clinical trial design, and generate hypotheses for mechanistic research. The applications span the entire value chain.
Predictive modeling for brand forecasting uses historical prescription data, patient demographics, disease prevalence trends, and competitive dynamics to project future market performance with far greater accuracy than traditional methods. These models can incorporate real-time signals—early launch uptake, formulary changes, competitor actions—and continuously refine predictions.
Clustering algorithms segment patients or physicians into distinct groups based on hundreds of variables simultaneously. Instead of simple demographics (age, gender, region), modern clustering incorporates treatment preferences, comorbidity patterns, practice characteristics, and prescribing behaviors to identify high-value targets for commercial engagement.
Natural language processing (NLP) extracts structured information from unstructured clinical notes in EMRs. This unlocks insights hidden in free-text physician documentation—symptom descriptions, treatment rationales, quality of life assessments—that claims data alone can’t capture.
Causal inference methods—propensity score matching, instrumental variables, difference-in-differences—address the fundamental challenge of RWD: patients aren’t randomized to treatments. These statistical approaches attempt to isolate treatment effects from confounding factors, generating RWE that regulatory agencies and payers will accept. The FDA’s 2023 guidance specifically discusses appropriate causal inference methodologies for generating regulatory-grade RWE.
Survival analysis (Kaplan-Meier curves, Cox proportional hazards models) evaluates time-to-event outcomes—progression-free survival, time to treatment discontinuation—critical for oncology and rare disease commercial strategies where long-term outcomes drive value demonstration.
The sophistication of analytics capabilities often determines commercial success. Companies that can deploy machine learning at scale—continuously learning from new data, refining predictions, triggering timely commercial actions—gain competitive advantages measured in months of launch performance and millions in revenue.
Commercial Applications That Actually Move Business Metrics
Theory is one thing. Impact on P&L is another. Let me walk through how leading pharma commercial organizations are applying RWD and advanced analytics to drive measurable business outcomes.
Market Sizing and Forecasting
Traditional market sizing relies on published epidemiology, survey data, and assumptions layered on assumptions. RWD-driven approaches analyze actual patient populations—diagnosed patients, treatment-naive patients, patients on standard of care—directly from claims and EMR data. The precision improvement is dramatic: instead of “approximately 50,000-80,000 eligible patients,” you get “67,342 diagnosed patients, of whom 23,456 are treatment-naive based on 12-month lookback.” This specificity transforms portfolio planning and resource allocation decisions.
Forecasting models incorporating real-world treatment patterns, persistence rates, and switching dynamics consistently outperform traditional models. One cardiovascular brand I’m familiar with reduced forecast error from 18% to 6% by incorporating RWD on competitive prescribing patterns and patient characteristics predictive of treatment choice.
Launch Excellence and Performance Tracking
Launch is the highest-stakes period in a brand’s lifecycle. RWD enables tracking weekly (sometimes daily) prescription trends, identifying early adopter characteristics, monitoring formulary status impact, and detecting geographic variation in uptake. This granular visibility allows rapid course correction—adjusting sales force deployment, modifying messaging, addressing access barriers—during the critical launch window.
Advanced organizations overlay predictive models that identify high-propensity prescribers before launch, prioritize outreach, and personalize messaging based on practice patterns and patient populations. The result: faster uptake, broader adoption, and optimized commercial investment.
HCP and Patient Targeting
Mass marketing is dead. Modern commercial models use RWD to identify and prioritize the specific physicians treating eligible patients and the specific patients most likely to benefit from therapy. Segmentation models incorporating hundreds of variables—physician specialty, patient volume, current treatment patterns, formulary alignment, practice setting—rank targets by potential value.
Patient-level analytics (on de-identified cohorts) identify those on suboptimal therapy, at risk of progression, or with characteristics suggesting treatment benefit. These insights drive digital campaigns, patient support programs, and payer negotiations focused on the populations where clinical and economic value is clearest.
Market Access and HEOR
Payers increasingly demand real-world evidence demonstrating that clinical trial efficacy translates to real-world effectiveness and value. RWD studies comparing costs and outcomes between treatment options—using claims data for costs and linked EMR data for clinical outcomes—provide this evidence.
According to a 2017 Value in Health study examining HTA agency policies across six countries, there’s growing acceptance of RWE in reimbursement decisions when studies meet methodological standards. Leading pharma companies are investing in RWD infrastructure specifically to generate HEOR evidence for pricing negotiations, formulary placement, and defending against payer restrictions.
Budget impact models incorporating actual patient populations (from RWD) rather than theoretical prevalence, real-world treatment patterns rather than assumed utilization, and observed costs rather than list prices, provide payers with credible projections they’re far more likely to accept.
Competitive Intelligence
Understanding competitor strategy—launch timing, pricing, positioning, prescriber targeting—provides critical strategic advantage. RWD on prescription trends, market share shifts, and treatment sequencing reveals competitive dynamics in near-real-time. This intelligence informs portfolio decisions, launch planning, lifecycle management, and resource allocation.
Safety Surveillance and Label Defense
Post-market safety monitoring using RWD identifies adverse events, drug-drug interactions, and safety signals across broader, more diverse populations than clinical trials. This fulfills regulatory requirements while also defending against competitor safety claims and supporting label expansion by demonstrating real-world safety profiles.
The Regulatory and HEOR Landscape: How RWE Changed the Game
Regulatory acceptance of RWE has evolved dramatically over the past five years. The FDA’s 21st Century Cures Act (2016) mandated evaluation of RWE to support approval of new indications for already-approved drugs. Since then, the agency has published multiple guidances detailing when and how RWE can support regulatory decisions.
The 2023 FDA guidance on RWE for drug and biological products outlines critical considerations: data relevance, data reliability, study design appropriateness, and transparency in reporting. The message is clear: well-designed RWE studies using quality data can inform regulatory decisions, including label expansions and post-market requirements.
A 2020 review in Pharmacoepidemiology and Drug Safety examined FDA use of RWE for rare disease approvals, finding that real-world data supported 30% of rare disease approvals between 2018-2019. This is particularly significant for orphan drugs where traditional trials are challenging due to small patient populations.
European regulators, including the EMA, have similarly embraced RWE. The European Medicines Agency’s 2023 data analysis and real-world evidence framework emphasizes the importance of data quality, appropriate study design, and transparency—echoing FDA positions while adding European perspectives on patient privacy (GDPR) and health technology assessment integration.
For market access, health technology assessment (HTA) bodies increasingly request RWE to complement clinical trial data. Organizations like NICE (UK), HAS (France), and major Continental European HTA authorities have published methodological guidance on incorporating RWD into health economic evaluations. The key requirement: rigorous methods addressing confounding and bias to generate credible comparative effectiveness evidence.
This regulatory evolution creates both opportunity and requirement. Companies that can generate regulatory-grade RWE efficiently gain competitive advantage in label expansion, payer negotiations, and lifecycle management. Those that can’t risk losing differentiation to competitors with stronger real-world evidence capabilities.
The Practical Reality: Challenges Everyone Faces
Honestly? Implementing effective RWD and commercial analytics programs is hard. Most organizations face persistent challenges that slow time-to-insight and limit value realization.
Data quality remains the number one barrier. Incomplete records, inconsistent coding, data entry errors, and unstructured formats plague RWD sources. One analysis found that 20-30% of EMR data requires significant cleaning before analysis. Claims data might have missing diagnosis codes or undercoding for reimbursement reasons. Registry data can be months delayed. These quality issues require sophisticated validation and curation processes.
Integration complexity is real. Linking disparate data sources—different patient identifiers, incompatible data formats, varying update frequencies—requires significant technical infrastructure. Many organizations underestimate the data engineering effort required to create truly integrated datasets, leading to projects that stall in the “80% complete” phase for months.
Privacy and compliance create legitimate constraints. GDPR and country-level privacy regulations strictly limit data use and sharing. De-identification must be robust, with risks of re-identification carefully managed. Data security requires enterprise-grade infrastructure. Navigating these requirements while maintaining data utility is a constant balancing act.
Talent gaps slow adoption. Effective use of RWD requires expertise in data science, statistics, clinical epidemiology, and pharma commercial strategy—a rare combination. Many analytics teams have strong business intelligence capabilities but lack advanced analytics skills. Others have data scientists without pharma domain knowledge. Building or acquiring this talent is expensive and time-consuming.
Vendor landscape complexity creates decision paralysis. The RWD ecosystem includes dozens of providers with overlapping but distinct capabilities. Understanding which combination of coverage, analytical tools, and domain expertise matches specific use cases requires deep market knowledge that most companies lack internally. This is where expert guidance becomes critical.
These challenges are surmountable but require intentional investment in infrastructure, talent, processes, and strategic partnerships. Organizations that address them systematically build sustainable competitive advantages in commercial analytics capabilities.
Navigating Your Data Partnership Options: What to Look For
The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities. The landscape includes providers with varying strengths across several key dimensions.
Coverage and Scale
Some providers maintain comprehensive longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types. Others focus on specific geographies or populations with greater depth. The choice depends on whether you need broad market intelligence or deep therapeutic area expertise.
Coverage breadth also varies by data recency. Some sources provide near-real-time prescription tracking (within days of dispensing), while others offer fully adjudicated claims with 3-6 month lag. Real-time data enables rapid competitive response but may lack complete diagnostic coding. Adjudicated data provides comprehensive clinical detail but limits agility.
Analytical Sophistication
Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. Some providers offer self-service tools allowing in-house teams to run analyses. Others operate on a full-service model with dedicated analytical support.
The choice depends on your internal capabilities and strategic priorities. Organizations with strong data science teams often prefer flexible, API-accessible datasets they can integrate into proprietary analytical workflows. Those lacking internal expertise benefit from full-service analytical support and pre-built use case templates.
Data Integration Depth
Some sources combine claims with complementary data—lab results, specialty pharmacy records, provider characteristics, patient demographics—creating richer patient profiles. This vertical integration enables analyses impossible with pure claims data, such as correlating prescription patterns with lab value trajectories or linking treatment adherence to socioeconomic factors.
Integration quality matters enormously. Superficial co-location of datasets provides limited value compared to true patient-level linkage with validated matching algorithms. Understanding a provider’s linkage methodology, match rates, and quality controls is essential for regulatory and HEOR applications.
Therapeutic Area Depth
General population databases provide broad coverage but may lack granularity in specialized therapeutic areas. Some providers maintain focused registries or enhanced datasets for specific conditions—oncology, rare diseases, specialty pharmacy products—with enriched clinical detail and outcomes tracking.
For specialized therapeutic areas, the gap between general claims data and disease-specific enhanced datasets can be substantial. Oncology analytics, for example, benefit enormously from linkage with tumor registries, biomarker testing, and specialty pharmacy adherence programs.
Cost Models and Commercial Terms
Pricing structures vary dramatically. Some providers charge per-query fees, others offer annual licenses for unlimited access, and still others use hybrid models with base licensing plus usage fees. Understanding total cost of ownership—including setup, training, analytical support, and ongoing access—is critical for budget planning.
Commercial flexibility also matters. Can you start with a pilot project before committing to large-scale licensing? Are there options for expanding coverage or analytical capabilities as needs evolve? Understanding these dimensions prevents costly lock-in to mismatched partnerships.
Expert Guidance for Provider Selection
Navigating this landscape requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem. The gap between understanding what claims data can do and identifying which specific provider matches your needs is substantial.
Expert advisors who understand both your business objectives and the provider landscape can accelerate your path to value while avoiding common pitfalls—mismatched coverage for your therapeutic areas, analytical capabilities that don’t support your use cases, integration challenges that delay insights, or cost structures that don’t align with long-term needs.
Understanding which providers excel at launch analytics versus longitudinal outcomes research, which offer superior integration for HEOR studies versus competitive intelligence, and which cost models make sense for exploratory versus production use cases requires deep market knowledge. This is why many leading pharmaceutical companies leverage strategic advisors to navigate provider selection before making substantial licensing commitments.
Getting Started: Practical Next Steps
If you’re a commercial analytics leader, HEOR director, or data science manager looking to enhance RWD and analytics capabilities, here’s where to focus your energy.
Define Requirements Before Evaluating Options
Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service), integration requirements (API access, data formats), compliance constraints, and budget parameters. This clarity prevents costly mismatches between provider capabilities and actual needs.
Most companies underinvest in requirements definition, jumping directly to provider evaluation. The result? Licensing decisions that seem logical in isolation but fail to support actual use cases. Expert consultants can help structure this requirements definition process to ensure you’re comparing options on the dimensions that actually matter.
Understand the Landscape Dimensions
The claims data market includes dozens of providers with overlapping but distinct capabilities. Key dimensions include data recency (real-time vs. adjudicated), geographic coverage, therapeutic depth, analytical tools, integration sophistication, and cost models.
Understanding these trade-offs—and how they map to your specific use cases—requires both pharmaceutical industry expertise and deep knowledge of the provider landscape. This is precisely where strategic guidance becomes valuable, helping you avoid the common pitfall of selecting based on brand recognition rather than capability fit.
Pilot Before Scaling
Start with a focused project to validate that your chosen approach answers your questions before committing to large-scale licensing agreements. Pilot projects reveal data quality issues, integration challenges, and analytical capability gaps that aren’t apparent in vendor presentations.
The most successful implementations begin with 2-3 month pilots targeting specific high-value use cases—market sizing for an upcoming launch, competitive intelligence for a mature brand, or HEOR evidence generation for payer negotiations. This focused approach demonstrates value quickly while building internal expertise.
Build Internal Capabilities Alongside Data Access
Data access alone doesn’t create insights. You need data engineers (to build pipelines), data scientists (for advanced analytics), clinical epidemiologists (for study design and interpretation), and commercial strategists (to translate insights into action).
The build-versus-partner decision depends on scale and strategic priorities. Large pharmaceutical companies with diverse portfolios often build internal centers of excellence. Mid-sized companies frequently partner with specialized analytics firms for advanced capabilities while maintaining core competencies in-house.
Establish Governance Early
Privacy compliance, data security, ethical use, and quality assurance require clear policies and oversight. Governance prevents downstream problems—regulatory violations, data breaches, ethical concerns—that could derail entire programs and damage corporate reputation.
This is particularly critical for GDPR compliance, where penalties can reach 4% of global revenue. Understanding how providers handle de-identification, data residency, processing agreements, and subject access requests is non-negotiable for European operations.
Why MEDDDICAL for Your Strategic RWE Guidance
Real-world data and commercial analytics aren’t theoretical concepts—they’re practical tools that either transform decision-making or waste substantial budgets. The difference lies in strategic guidance that connects your business objectives with the right combination of data capabilities, analytical approaches, and domain expertise.
At MEDDDICAL, we’ve built our advisory practice on deep expertise in both pharmaceutical commercialization and the real-world evidence ecosystem. We understand what drives launch success, what payers demand for market access, and what regulators accept for label expansions. We also know the provider landscape intimately—which capabilities matter for which use cases, where quality varies, and how cost structures align with different strategic priorities.
Our value isn’t in listing data providers—it’s in understanding your specific challenges and navigating you to the right solutions. Whether you’re sizing the Continental European opportunity for an upcoming launch, building HEOR evidence for market access negotiations, tracking competitive dynamics post-LOE, or developing patient journey insights for commercial strategy, we provide the strategic guidance that accelerates your path to value.
We help you define requirements that actually match your use cases, evaluate options across the dimensions that matter, structure pilot projects that demonstrate ROI quickly, and build internal capabilities that create sustainable competitive advantage. The gap between licensing claims data and extracting actionable intelligence is substantial—this is where expert guidance becomes critical.
The pharmaceutical companies that thrive in the RWE era aren’t necessarily those with the biggest data budgets. They’re the ones that make strategic choices about where to invest, which capabilities to build versus partner, and how to translate data access into commercial impact. Navigating this landscape requires expertise that most organizations lack internally.
Let’s have a conversation about your specific challenges. Contact us to discuss your real-world evidence strategy and explore how strategic guidance can accelerate your commercial analytics program while avoiding costly mismatches between provider capabilities and actual business needs.
Sources & References
- FDA. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff (2025). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices
- FDA. Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products: Draft Guidance for Industry (2024). https://www.fda.gov/media/176989/download
- Dang A. Real-World Evidence: A Primer. Pharmaceut Med. 2023;37(1):25-36. https://pubmed.ncbi.nlm.nih.gov/36604368/
- Zhu R, et al. Clinical Pharmacology Applications of Real-World Data and Real-World Evidence in Drug Development and Approval—An Industry Perspective. Clin Pharmacol Ther. 2023;114(3):516-527. https://pubmed.ncbi.nlm.nih.gov/37393555/
- Kolluri S, et al. Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: A Review. AAPS J. 2022;24(1):19. https://pubmed.ncbi.nlm.nih.gov/34984579/
- FDA. Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry (2023). https://www.fda.gov/media/171667/download
- Makady A, et al. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value Health. 2017;20(4):520-532. https://pubmed.ncbi.nlm.nih.gov/28407993/
- Wu J, et al. Use of real-world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions. Pharmacoepidemiol Drug Saf. 2020;29(10):1213-1218. https://pubmed.ncbi.nlm.nih.gov/32003065/
- Dagenais S, et al. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design. Clin Pharmacol Ther. 2022;111(1):77-89. https://pubmed.ncbi.nlm.nih.gov/34839524/
- Basch E, et al. New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment. JAMA. 2019;321(14):1359-1360. https://pubmed.ncbi.nlm.nih.gov/30964519/
- Yuan L, et al. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making. Clin Transl Sci. 2024;17(1):e13702. https://pubmed.ncbi.nlm.nih.gov/38093484/
- FDA. Framework for FDA’s Real-World Evidence Program (2018). https://www.fda.gov/media/120060/download